Proteomic Prediction of Clinical Benefit in HNSCC
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 352
- 试验地点
- 3
- 主要终点
- Identification of patients who will benefit from treatment with EGFR and/or VEGF inhibitors based on serum proteomic profiles
研究概览
简要总结
RATIONALE: Studying samples of blood in the laboratory may help doctors learn more about cancer. It may also help doctors predict how well patients will respond to treatment.
PURPOSE: This research study is looking at proteins in blood samples to predict treatment benefit in patients with recurrent and/or metastatic squamous cell head and neck cancer.
详细描述
OBJECTIVES:
- To identify head and neck squamous cell cancer patients who will benefit from treatment with the EGFR inhibitors (i.e., erlotinib hydrochloride, gefitinib, and cetuximab) and VEGF inhibitor (i.e., bevacizumab), based on predictive proteomic profiles in patient blood samples.
OUTLINE: This is a multicenter study.
Blood samples are analyzed for proteomic profile to determine good and bad prognoses in patients treated with or without EGFR inhibitors and/or a VEGF inhibitor.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Identification of patients who will benefit from treatment with EGFR and/or VEGF inhibitors based on serum proteomic profiles
时间窗: upon analysis of each patient tissue collection
次要结局
未报告次要终点
研究者
Barbara Murphy, MD
Professor of Medicine, Medical Oncologist
Vanderbilt-Ingram Cancer Center